

# Pegloticase (Krystexxa)

Provider Order Form rev. 12/19/2023



## PATIENT INFORMATION

Referral Status:  New Referral  Updated Order  Order Renewal

Patient Name: \_\_\_\_\_ DOB: \_\_\_\_\_ Patient Phone: \_\_\_\_\_

Patient Address: \_\_\_\_\_ Patient Email: \_\_\_\_\_

Allergies: \_\_\_\_\_  NKDA Weight (lbs/kg): \_\_\_\_\_ Height (in/cm): \_\_\_\_\_

Sex:  M /  F Date of Last Infusion: \_\_\_\_\_ Next Due Date: \_\_\_\_\_ Preferred Location: \_\_\_\_\_

## DIAGNOSIS (Please provide ICD-10 code in space provided)

Gouty arthropathy: \_\_\_\_\_

Other: \_\_\_\_\_ Description: \_\_\_\_\_

## REQUIRED INFORMATION

G6PD Results \_\_\_\_\_

Baseline uric acid level \_\_\_\_\_ & date \_\_\_\_\_

## THERAPY ADMINISTRATION & DOSING

Krystexxa 8mg IV every 2 weeks with weekly oral methotrexate 15mg and daily folic acid 1mg<sup>1</sup>

Methotrexate contraindicated and patient is on Krystexxa Monotherapy 8mg IV every 2 weeks

Monitor patient for hypersensitivity reaction for a period of 60 minutes following each infusion

<sup>1</sup>Begin weekly Methotrexate and Folic Acid 4 weeks prior to the start of Krystexxa infusions.

## FREQUENCY (Choose one)

Every 2 weeks

Other: \_\_\_\_\_

## ADDITIONAL ORDERS

## LABORATORY ORDERS

Obtain serum uric acid level prior to each infusion (or may use result obtained within 48 hrs prior to infusion).

Other: \_\_\_\_\_

## PRE-MEDICATION ORDERS

All premedication administered 30mins prior to infusion

Loratadine 10mg PO

Tylenol 500mg PO

Solumedrol 125mg IV

Benadryl  25 mg /  50mg  PO /  IV (**must have per PI**)

Other: \_\_\_\_\_

## NURSING

Hold infusion and notify provider for:

- Uric acid level greater than 6 mg/dL for 2 consecutive treatments (lab orders below).
- Patient has had more than 4 weeks between treatments (due to increased risk for adverse reaction).
- Patient reports continued use of uric acid lowering agents (allopurinol, febuxostat, probenecid, etc.)
- Hypertension (170/90 or symptomatic)

Provide nursing care per Nursing Procedure, including Hypersensitivity Reaction Management Protocol and post-procedure observation

## PROVIDER INFORMATION

Preferred Contact Name: \_\_\_\_\_ Preferred Contact Email: \_\_\_\_\_

Ordering Provider: \_\_\_\_\_ Provider NPI: \_\_\_\_\_

Referring Practice Name: \_\_\_\_\_ Phone: \_\_\_\_\_ Fax: \_\_\_\_\_

Practice Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ Zip Code: \_\_\_\_\_

## REQUIRED DOCUMENTATION CHECKLIST (Additional documentation required for processing and insurance approval)

**Required Documentation:** Patient demos, copy of front and back of primary and secondary insurance, 2 most recent OVN including treatment failures or contraindications with colchicine, NSAIDs, steroids, Febuxostat, Allopurinol, Probenecid. flares in 12 months, Gouty arthritis, Tophus

**Required Labs:** G6PD, UA level, CRP/ESR

Provider Name (print) \_\_\_\_\_

Provider Signature \_\_\_\_\_

Date \_\_\_\_\_

Order valid for one year unless otherwise indicated. IV solutions/diluents may be substituted as allowed per manufacturer's instructions as necessitated by product availability.